Table.
Baseline characteristics
| Anti-N IgG seropositive group (n=91) | Anti-N IgG seronegative group (n=58) | p value* | ||
|---|---|---|---|---|
| Female | 43 (47) | 25 (43%) | 0·74 | |
| Male | 48 (53%) | 33 (57%) | .. | |
| Age, years | 28 (24–37) | 35 (26–44) | 0·015 | |
| Body-mass index | .. | .. | 0·91 | |
| Underweight | 4 (4%) | 4 (7%) | .. | |
| Normal | 42 (46%) | 25 (43%) | .. | |
| Overweight | 25 (27%) | 17 (29%) | .. | |
| Obese | 20 (22%) | 12 (21%) | .. | |
| Smoker | 41 (45%) | 27 (47%) | 0·99 | |
| Alcohol | 50 (55%) | 27 (47%) | 0·41 | |
| Health worker | 4 (4%) | 4 (7%) | 0·71 | |
| Race | .. | .. | 0·011 | |
| Black | 76 (84%) | 45 (78%) | .. | |
| Mixed race | 13 (14%) | 4 (7%) | .. | |
| White | 1 (1%) | 6 (10%) | .. | |
| Other | 1 (1%) | 3 (5%) | .. | |
| Hypertension | 2 (2%) | 1 (2%) | >0·99 | |
| Respiratory system | 2 (2%) | 2 (3%) | 0·64 | |
| Diabetes | 1 (1%) | 0 | >0·99 | |
| HbA1c level† | .. | .. | >0·99 | |
| Low | 0 | 1 | .. | |
| Normal | 1 | 16 | .. | |
| High | 0 | 0 | .. | |
| Time between doses, days | 28 (28–33) | 28 (28–29) | 0·27 | |
| Time 2 weeks after second dose, days | 14 (14–14) | 14 (14–14) | 0·79 | |
| Time 6 months after second dose, days | 149 (144–154) | 146 (142–154) | 0·89 | |
Data are n (%) and median (IQR).
*
p value comparing characteristics between baseline antiN IgG seropositive and baseline anti-N IgG seronegative individuals.
†
Measured in safety cohort only.